Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

iBio Fiscal Q3 2024 Earnings Report - CapyFin

iBio

🇺🇸 NYSE:IBIO

View Company

Overview Earnings Dividends Seasonality Metrics

May 13, 2024

•

Mar 31, 2024

iBio Q3 2024 Earnings Report

iBio's financial performance for Q3 2024 reflected a focus on strategic partnerships and cash preservation.

Key Takeaways

iBio reported no revenue for Q3 2024. The company's net loss from continuing operations was $2.6 million, or $0.71 per share. iBio focused on strategic partnerships, including a collaboration with AstralBio, and cash preservation, which led to a decrease in R&D and G&A expenses.

iBio entered into a collaboration with AstralBio to develop novel antibodies for cardiometabolic diseases.

The company sold its early-stage PD-1 asset to Otsuka Pharmaceutical for $1M upfront with potential downstream payments of up to $52.5M.

iBio strengthened its cash position through warrant exercises, generating approximately $4.3M in proceeds.

R&D and G&A expenses decreased by approximately 66% and 23%, respectively, reflecting a cash preservation strategy.